Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 1/2021

01-01-2021 | Primary Myelofibrosis | Images

Loss of Normal Polyploid Spectrum as Marker of Clonality in Acute Megakaryoblastic Leukemia Evolving from Pre-Existing Primary Myelofibrosis

Authors: Nishit Gupta, Aditi Mittal, Tina Dadu, Anil Handoo

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2021

Login to get access

Excerpt

Normal megakaryocytes are polyploid cells with DNA content ranging from tetraploid to 128 N and originate from the diploid (2 N) promegakaryoblasts following endomitosis. Acute megakaryoblastic Leukemia (AML-M7) is characterized by differentiation blockade at the promegakaryoblast stage and induction of terminal polyploidy can be a potential therapeutic approach [1]. …
Literature
1.
go back to reference Mazzi S, Lordier L, Debili N, Raslova H, Vainchenker W (2018) Megakaryocyte and polyploidization. Exp Hematol 57:1–3CrossRef Mazzi S, Lordier L, Debili N, Raslova H, Vainchenker W (2018) Megakaryocyte and polyploidization. Exp Hematol 57:1–3CrossRef
2.
go back to reference Feng G, Gale RP, Cui W, Cai W, Huang G, Xu Z et al (2015) A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Experimental Hematol Oncol 5(1):12CrossRef Feng G, Gale RP, Cui W, Cai W, Huang G, Xu Z et al (2015) A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Experimental Hematol Oncol 5(1):12CrossRef
Metadata
Title
Loss of Normal Polyploid Spectrum as Marker of Clonality in Acute Megakaryoblastic Leukemia Evolving from Pre-Existing Primary Myelofibrosis
Authors
Nishit Gupta
Aditi Mittal
Tina Dadu
Anil Handoo
Publication date
01-01-2021
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2021
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01355-z

Other articles of this Issue 1/2021

Indian Journal of Hematology and Blood Transfusion 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine